Monitoring of verapamil enantiomers concentration in overdose

Clinical Toxicology

Volumn 44, Issue 2, 2006, Pages 169-171

  Wilimowska, Jolanta ^a   Piekoszewski, Wojciech ^a,b   Krzyanowska Kierepka, Ewa ^a   Florek, Ewa ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF FORENSIC RESEARCH   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Chiral liquid chromatography; Pharmacokinetics; Verapamil overdose

Indexed keywords

DOBUTAMINE; NORADRENALIN; PARACETAMOL; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; BLOOD PRESSURE; CASE REPORT; CORONARY ARTERY DISEASE; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MONITORING; DRUG OVERDOSE; ENANTIOMER; ENDOTRACHEAL INTUBATION; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; PERSONALITY DISORDER; STEREOCHEMISTRY; BLOOD; CHEMISTRY; INTOXICATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; MONITORING; STEREOISOMERISM;

BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OVERDOSE; STEREOISOMERISM; VERAPAMIL;

EID: 33645961561     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650500514541     Document Type: Article

References (12)

1. Brocks DR, Jamali F. Stereochemical aspects of pharmacotherapy. Pharmacotherapy 1995; 15(5):551-564.
2. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmidebergs Arch Pharmacol 1993; 348(3):332-337.
3. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P4502C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmidebergs Arch Pharmacol 1995; 353(1):116-121.
4. Karim A, Piergies A. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral inpute rate, or both. Clin Pharmacol Ther 1995; 58(2):174-184.
5. Busse D, Fromm MF, Morike K. Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: An investigation comparing single and multiple dosing. Clin Pharmacol Ther 2001; 69(5):324-332.
6. Klimaszyk D. ECG disorders in the course of acute suicidal poisonings by verapamil. Przegl Lek 2000; 57(10):600-605.
7. Lapostolle F, Bourdain F, Adnet F, Benaissa A, Muszynski J, Baud F. Acute verapamil poisoning. A proposal of a strategy for therapeutic management. Ann Fr Anesth Reanim 2000; 19(8):607-610.
8. Oe H, Taniura T, Ohgitani N. A case of severe verapamil overdose. Jpn Circ J 1998; 62(1):72-76.
9. Wilimowska J, Piekoszewski W, Florek E. The methodology of the stereoselective determination of verapamil in serum (in press. Problems of Forensic Sciences).
10. Vlcek J, Macek K, Hulek P, Bratowa M, Fendrich Z. Pharmacokinetic parameters of Verapamil and its active metabolite norverapamil in patients with hepatopathy. Arzneimittel Forschung/Drug Res 1995; 45(2):146-149.
11. Buckley CD, Aronson JK. Prolonged half-life of verapamil in a case of overdose: implications for therapy. Br J Clin Pharmacol 1995; 39(6):680-683.
12. Kivisto KT, Neuvonen PJ, Tarssanen L. Pharmacokinetics of verapamil in overdose. Hum Exp Toxicol 1997; 16(1):35-37.